NeoGenomics (NEO) Reports In-Line Q4 EPS, Offers Guidance

NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $106.9 million versus the consensus estimate of $104.24 million.

GUIDANCE:

NeoGenomics sees FY2020 revenue of $464-474 million, versus the consensus of $448.3 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Pfizer lung cancer drug misses survival goal in Phase 3 trial